WELCOME LETTER

Dear Reader, Welcome to the 2021 edition of the United States Pharmaceutical and Biopharmaceutical Industry Report.

Over the past year, the United States life sciences ecosystem faced one of its greatest ever tests in responding to COVID-19. Fortunately, thanks to years of research, development and risk taking, the industry proved up to task, displaying its remarkable dynamism. Therapeutics and vaccines were brought to market on timelines previously considered to be impossible and, at least temporarily, public opinion of the sector spiked as the industries’ valiant efforts were brought to light. Beyond the headlines, companies continued to build on the progress of the previous decades, despite the many challenges COVID presented for clinical trials and supply chains. Undeterred, the industry obtained 53 novel drug approvals, across indications ranging from precision oncology to peanut allergy. With gene editing, cell-based therapies, and profoundly new ways of manipulating immune cells to target cancers, today the industry has a far greater toolbox to treat disease than previously imagined. With many of the great uncertainties of the pandemic now behind us, it is crucial for investors, pharmaceutical executives, manufacturers and scientific researchers involved in the US pharma and biopharma industry to remain unified and informed. The way in which groups across industry, academia, government and the broader health-care system have come together to fight this pandemic has been inspiring to many. And indeed, continuing to partner in this way will be critical in successfully navigating public health challenges of the future. The following pages offer widespread coverage of the state of the US pharmaceutical and biopharmaceutical industry, including big pharma and its blockbuster drugs, emerging biotech and their innovative drug pipelines, and the different service providers across the value chain, from CDMOs and CROs to AI and big data platform companies. We sincerely hope that you have a great conference, full of business and networking opportunities. Thank you for your participation in CPhI Discover, and we hope you enjoy reading our 2021 edition of the United States Pharma and Biopharma Industry Report.

SECTIONS

image
image
image
image
image
image
image